

## **Revisión de la Literatura VIH. SEIMC 2019**

**Dr. José Ramón Arribas**

*Hospital Universitario La Paz, Madrid*

### **Epidemiología**

1. Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV Epidemic. JAMA 2019; 321:844–2
2. El-Sadr WM, Mayer KH, Rabkin M, Hodder SL. AIDS in America - Back in the Headlines at Long Last. N Engl J Med 2019; :NEJMp1904113.
3. Victoria Hernando, Olivier Nuñez, Marta-Ruiz-Algueró y Asunción Díaz. Estimación del continuo de atención del VIH en España, 2016  
<http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/publicaciones/profSanitarios/CascadaWEBDxTTOHIV22Novbre17.pdf>
4. Área de Vigilancia de VIH y Comportamientos de Riesgo. Vigilancia Epidemiológica del VIH y sida en España
5. Sistema de Información sobre Nuevos Diagnósticos de VIH y Registro Nacional de Casos de Sida. Plan Nacional sobre el Sida - S.G. de Promoción de la Salud y Epidemiología / Centro Nacional de Epidemiología -ISCIII. Madrid; Nov 2017 Source:  
[https://www.msrebs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/documentos/InformeHIV\\_SIDA\\_2018\\_21112018.pdf](https://www.msrebs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/vigilancia/documentos/InformeHIV_SIDA_2018_21112018.pdf)

### **Prevención**

6. Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet Published Online First: 2 May 2019. doi:10.1016/S0140-6736(19)30418-0
7. Grulich AE, Guy R, Amin J, Jin F, Selvey C, Holden J, et al. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. The Lancet HIV 2018; 5:e629–e637.

8. Hare CB et al. The phase 3 discover study: daily F/TAF or F/TDF for HIV preexposure prophylaxis. Oral abstract LB 104LB. CROI 2019
9. Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. JAMA 2019; 321:1380–1390.
10. Molina J-M, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. The Lancet Infectious Diseases 2018; 18:308–317.

### **Tratamiento**

11. Labhardt ND, Ringera I, Lejone TI, Klimkait T, Muhairwe J, Amstutz A, et al. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho. JAMA 2018; :1–10
12. Guías GESIDA 2019. [http://gesida-seimc.org/wp-content/uploads/2019/02/Guia\\_Tar\\_Gesida\\_Ene\\_2019.pdf](http://gesida-seimc.org/wp-content/uploads/2019/02/Guia_Tar_Gesida_Ene_2019.pdf)
13. Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet 2019; 393:143–155
14. Orkin C, Squires KE, Molina J-M, Sax PE, Wong W-W, Sussmann O, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis 2018; 68:535–544.
15. Molina J-M, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. The Lancet HIV 2018; 5:e211–e220.

16. Johnson M, Kumar P, Molina J-M, Rizzardini G, Cahn P, Bickel M, et al. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-Virologic Suppression Through 48 Weeks. *JAIDS Journal of Acquired Immune Deficiency Syndromes* 2019; :1–31.
17. Libre JM, Hung C-C, Brinson C, Castelli F, Girard P-M, Kahl LP, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. *Lancet* Published Online First: 5 January 2018. doi:10.1016/S0140-6736(17)33095-7
18. Aboud M, Kaplan R, Lombaard J, Zhang F, Hidalgo JA, Mamedova E, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. *The Lancet Infectious Diseases* 2019; 19:253–264.
19. Pialoux G, et al Phase 3 study of fostemsavir in heavily treatment-experienced HIV-1-infected participants: BRIGHTE week 24 subgroup analysis in randomized cohort subjects.. *AIDS* 2018; Amsterdam, the Netherlands; July 23-27, 2018; Abst. THPEB045.
20. Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. *Nature* 2018; 561:479–484.
21. Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. *N Engl J Med* 2018; 379:645–654.
22. Wang C-Y, Wong W-W, Tsai H-C, Chen Y-H, Kuo B-S, Lynn S, et al. Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption. *N Engl J Med* 2019; 380:1535–1545.
23. Swindells S et al. Long-acting cabotegravir + rilpivirine as maintenance therapy: atlas week 48 results. CROI 4 – 7 March 2019, Seattle. Late breaker oral abstract 139
24. Orkin C et al. Long-acting cabotegravir+rilpivirine for hiv maintenance: FLAIR week 48 results. CROI 4 – 7 March 2019, Seattle. Late breaker oral abstract 140LB

### **Curación**

25. Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. *Nature Publishing Group* 2018; 24:923–926.
26. Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppas D, Salgado M, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. *Nature* 2019; 568:244–248.
27. Salgado M, Kwon M, Gálvez C, Badiola J, Nijhuis M, Bandera A, et al. Mechanisms That Contribute to a Profound Reduction of the HIV-1 Reservoir After Allogeneic Stem Cell Transplant. *ANNals of internal medicine* 2018; 169:674–683.

### **Embarazo**

28. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. *N Engl J Med* 2018; 379:979–981

### **Enfermedades Oportunistas**

29. Meintjes G, Stek C, Blumenthal L, Thienemann F, Schutz C, Buyze J, et al. Prednisone for the Prevention of Paradoxical Tuberculosis-Associated IRIS. *N Engl J Med* 2018; 379:1915–1925.
30. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. *N Engl J Med* 2019; 380:1001–1011.
31. Muftuoglu M, Olson A, Marin D, Ahmed S, Mulanovich V, Tummala S, et al. Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. *N Engl J Med* 2018; 379:1443–1451.
32. Cortese I, Muranski P, Enose-Akahata Y, Ha S-K, Smith B, Monaco M, et al. Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. *N Engl J Med* 2019; :NEJMoa1815039–8.